



Early QT/TQT Studies

DVCR's Expertise in EPQT/TQT

Dr. Vince Clinical Research (DVCR) advances medicine by leveraging technology and expertise to evaluate how medications affect the cardiac conduction cycle, including Early Precision QT (EPQT) and Thorough QT (TQT) analysis. Our contemporary approach to cardiac studies ensures that sponsors receive accurate data while keeping volunteer safety at the forefront.

Market Leading Technology

Within DVCR's Phase 1 Unit are 48 individual monitoring channels on the state-of-the-art Hillrom Surveyor™ cardiac telemetry system.

Features of the Hillrom Surveyor™ telemetry system



Cardiac data archived on-site



Data transmission directly to Clario's cloud-based portal



Reduced number of electrodes on participants



Remote monitoring of tracing quality to reduce data collection interruptions



Clario Certified Site

DVCR has partnered with Clario to offer advanced EPQT studies at its certified Phase I unit. This collaboration enables sponsors to collect high-quality cardiac safety data earlier in development, with the potential to meet ICH E14 requirements and waive TQT studies. Integrated technology and streamlined data collection improve both efficiency and volunteer experience.

"It was quickly obvious that the clinical pharmacology unit built by [DVCR] is exceptionally well-suited to conduct these complex trials given the site's integrated technologies, state-of-the-art telemetry system, and deep clinical experience."

Robert Kleiman, M.D., Chief Science and Regulatory Advisor, Cardiology, Clario

